Abstract：Objective To investigate the clinical effect of Gemcitabine with maintenance chemotherapy in the treatment of advanced lung squamous cell carcinoma. Methods A total of 68 patients with advanced lung squamous cell carcinoma admitted to Anshan Cancer Hospital from July 2016 to January 2020 were selected as the research objects. They were divided into the control group and the experimental group according to the random number table method, with 34 cases in each group. In the control group, best supportive treatment was used, and in the experimental group, Gemcitabine with maintenance chemotherapy was adopted. The clinical effect, incidence of adverse reactions and progression-free survival were compared between the two groups. Results There were no statistically significant differences in the total effective rate and disease control rate between the two groups (P＞0.05). The incidence rates of liver function damage, gastrointestinal reaction, hair loss and neurotoxicity in observation group were lower than those in control group, and the differences were statistically significant (P＜0.05). There were no statistically significant differences in the incidence rates of renal function impairment and rash between the two groups (P＞0.05). The progression-free survival in the experimental group was longer than that in the control group, and the difference was statistically significant (P＜0.05). Conclusion The clinical effect of maintenance chemotherapy with Gemcitabine for patients with advanced lung squamous cell carcinoma is the same as the best supportive treatment, but the incidence of adverse reactions is low and the progression-free survival period is high. It is worthy of promotion and application in future clinical practice.
毕大鹏. 吉西他滨同药维持化疗治疗晚期肺鳞癌的临床效果[J]. 中国当代医药, 2021, 28(12): 112-114转118.
BI Da-peng. Clinical effect of maintenance chemotherapy with Gemcitabine in the treatment of advanced lung squamous cell carcinoma. 中国当代医药, 2021, 28(12): 112-114转118.
京公网安备 11010502046607号